Biocon’s stock is witnessing a sharp rally following the launch of Yesintek (ustekinumab-kfce) in the United States by its subsidiary Biocon Biologics. The company’s shares are currently trading at Rs. 328.00, up by 2.21%, adding 7.10 points from its previous close of Rs. 320.90 on the Bombay Stock Exchange (BSE).
The stock opened at Rs. 325.25, reaching a high of Rs. 328.75 and a low of Rs. 321.15 during the trading session, with 42,090 shares exchanged on the counter so far.
Market Performance Overview
- 52-week high: Rs. 404.60 (21-Jan-2025)
- 52-week low: Rs. 244.40 (20-Mar-2024)
- One-week high: Rs. 340.00
- One-week low: Rs. 315.50
- Market Capitalization: Rs. 38,581.28 crore
Shareholding Structure
- Promoters: 60.64%
- Institutional Investors: 21.02%
- Non-Institutional Investors: 18.34%
Biocon Biologics Expands U.S. Presence with Yesintek
Biocon Biologics’ Yesintek is among the first biosimilars of Stelara (ustekinumab) to enter the U.S. market. The drug has been approved for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering patients a cost-effective alternative for managing chronic autoimmune conditions.
Yesintek will be available in all formulations currently offered by Stelara, including:
- 45 mg/0.5 mL PFS
- 90 mg/mL PFS
- 45 mg/0.5 mL vial
- 130 mg/26 mL vial
Biocon’s Strong Position in Biotechnology
As India’s largest and Asia’s leading biotechnology company, Biocon has solidified its presence in the biopharmaceutical and research services sector. The company is an innovation-driven enterprise focused on providing affordable healthcare solutions to patients globally, especially for chronic diseases.
The successful launch of Yesintek marks a significant milestone in Biocon Biologics’ global expansion strategy, positioning the company among the leading biosimilar players in the U.S. market.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.